| v-Raf murine sarcoma viral oncogene mutations are common in ovarian serous bordeline tumors. | sarcoma,ovarian, |
| High oncogenic BRAF levels trigger autophagy, which may have a role in melanoma tumor progression. | skin, |
| Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. | skin, |
| PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. | skin, |
| In melanoma cells, oncogenic (V600E) BRAF signaling downregulates PDE5A through the transcription factor BRN2, leading to increased cGMP and Ca2+ and the induction of invasion through increased cell contractility. | skin, |
| Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. | thyroid, |
| Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. | skin, |
| Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. | skin, |
| Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. | skin, |
| tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGFbeta-induced epithelial-mesenchymal transition, through a MAPK-dependent process | thyroid, |
| c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. | lung, |
| BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. | colorectal, |
| Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. | thyroid, |
| papillary thyroid cancers in young patients display a low prevalence of the already identified oncogenic alterations; the increasing prevalence with age is mainly due to V600E BRAF mutation | thyroid, |
| Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropa n-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. | sarcoma, |
| Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. | cervical,thyroid, |
| A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. | colorectal, |
| these results link epigenetic genes to methylation and suppression of tumor suppressor genes as a mechanism involved in BRAFV600E-promoted melanoma tumorigenesis and uncover a novel molecular signature that predicts a poor prognosis of melanoma. | skin, |
| It was concluded that extracellular kinase-mediated up-regulation of c-myc by K-Ras or B-Raf oncogenes disrupts the establishment of apical/basolateral polarity in colon epithelial cells independently of its effect on proliferation. | colorectal, |
| Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. | sarcoma, |